Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Monoglyceride docosahexaenoic acid* refers to docosahexaenoic acid (DHA) chemically bound as a monoglyceride, making it a structured lipid distinct from the standard triglyceride or free fatty acid forms. As a highly bioavailable form of DHA, MAG-DHA displays improved cellular uptake and efficacy over traditional forms. DHA is an omega-3 polyunsaturated fatty acid critical for membrane structure and function, particularly in neural and ocular tissues. MAG-DHA has shown anti-cancer activity in preclinical models—either alone or in combination with chemotherapy (carboplatin)—reducing tumor cell proliferation and invasion, inducing apoptosis and autophagy, and suppressing EGFR/ERK signaling. MAG-DHA also shows utility as a nutraceutical or feed additive for improving growth, tissue DHA content, and intestinal health in aquatic organisms. It is primarily considered a dietary supplement and experimental nutraceutical; the pharmaceutical potential is under investigation[1][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on monoglyceride docosahexaenoic acid.